Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Egetis Therapeutics AB is a Sweden-based pharmaceutical company specializing in the development of innovative drugs for serious rare diseases with unmet medical needs in the orphan drug segment. Formerly known as PledPharma AB, it rebranded in December 2020 and focuses on late-stage projects addressing niche therapeutic areas. Its pipeline features Emcitate, designed to treat monocarboxylate transporter 8 (MCT8) deficiency, a rare and debilitating genetic disorder lacking approved therapies. Another key candidate, Aladote, aims to mitigate acute liver injury risks from acetaminophen overdose and is advancing through phase IIb/III trials. Previously, PledOx targeted chemotherapy-induced nerve damage. Headquartered in Stockholm and founded in 2006, Egetis Therapeutics AB employs around 40 professionals dedicated to integrated drug development. Operating in the biotechnology sector, it plays a vital role in advancing treatments for orphan indications, contributing to the global effort against underserved rare conditions through rigorous clinical progression.
kr 5.39
kr 0.08 (-1.46%)
Live · 05:22 PM · Twelve Data
The business is unprofitable at the operating level (-528.85% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 35.4% YoY with margins expanding 169.2pp.
ROIC dropped from -40.07% to -50.15%, capital efficiency is deteriorating. Negative free cash flow of -kr 269M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 63M
▲ +35.4% YoY
Net Income (TTM)
-kr 374M
▲ +0.3% YoY
Op. Margin
-583.86%
▲ +169.2pp YoY
ROIC
-50.15%
▼ -10.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 267M
▼ -17.8% YoY
Op. Cash Flow (TTM)
-kr 265M
▼ -17.2% YoY
Net Debt
-kr 125M
Net Cash Position
Cash & Equiv.
kr 216M
3Y CAGR: +40.5%
Continue Research
Egetis Therapeutics AB (EGTX.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Egetis Therapeutics AB scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Egetis Therapeutics AB scores 40 out of 100 on Intrinsiqq's quality score, passing 3 of 6 checks, which makes it a mixed business on these measures. Recent fundamentals include a -583.9% operating margin and a -50.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh EGTX.XSTO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.